Researchers Submit Patent Application, "Methods For Treating Neuroblastoma", for Approval (USPTO 20240165063).
In: Cancer Vaccine Week, 2024-06-10, S. 116-116
serialPeriodical
Zugriff:
Researchers Bruckheimer and Gerner have submitted a patent application for a pharmaceutical therapy called a-difluoromethylornithine (DFMO) for the treatment of neuroblastoma, a childhood cancer. The application suggests using genetic testing to determine patient suitability for treatment with DFMO and provides specific dosing and administration instructions. The therapy may be used alone or in combination with other agents such as non-steroidal anti-inflammatory drugs, polyamine transporter inhibitors, chemotherapeutics, or immunomodulatory agents. This patent application offers potential methods for preventing or curing neuroblastoma, particularly in patients with high-risk disease. [Extracted from the article]
Copyright of Cancer Vaccine Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Researchers Submit Patent Application, "Methods For Treating Neuroblastoma", for Approval (USPTO 20240165063).
|
---|---|
Zeitschrift: | Cancer Vaccine Week, 2024-06-10, S. 116-116 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6810 (print) |
Schlagwort: |
|
Sonstiges: |
|